RxDoctor Payments Data

Sakshi Sethi, MD

Pulmonary Disease · Danbury, CTNPI 1518270826

Payments from drug & device makers

$9,056in general payments, 2019–2025

Across 16 payments — averaging $566.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$9K
  • Regeneron Healthcare Solutions, Inc.$58
  • Sanofi$50
  • GSK$42
  • Pfizer$39
  • Lilly USA, LLC$28
  • plus $100 from 5 others

What the payments were for

  • Food & beverage$25882%
  • Education$5818%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$9,056 in reported general payments places this provider in the 75th percentile of 255 pulmonary disease providers in Connecticut.

See all pulmonary disease providers in Connecticut

Medicare billing

Part B allowed, 2024
$156,481
Medicare patients
527
Services billed
1,401

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter98$99,100
Breo ElliptaFluticasone/Vilanterol85$65,185
Dupixent PenDupilumab13$46,273
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr54$43,198
Incruse ElliptaUmeclidinium Bromide27$12,709
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate43$8,421
SymbicortBudesonide/Formoterol Fumarate25$7,703
Arnuity ElliptaFluticasone Furoate16$5,803
Albuterol Sulfate HfaAlbuterol Sulfate121$4,565
Ventolin HfaAlbuterol Sulfate33$4,106
Wixela InhubFluticasone Propion/Salmeterol18$3,090
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$1,476
Azithromycin45$720
Ipratropium Bromide24$695
Montelukast Sodium21$526

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta$42$225,995280 claims
AstraZenecaSymbicort$12$7,70325 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 255 pulmonary disease providers in Connecticut.

Other pulmonary disease in Danbury

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →